BIOMAT Database Logo BIOMAT Database Logo

[Tolerance of the polyvalent adsorbed influenza vaccine Alorbat]. 1979

M Peukert, and J Pollter

A good local and systemic tolerance of the influenza virus vaccine Alorbat was observed after a single administration in 469 patients or after a second administration within 4--6 weeks in 132 patients. An improved manufacturing process led to a higher purity of the vaccine (less protein) and therefore to a diminuation of systemic reactions. In most cases, the local reactions observed cannot be attributed to a local irritation by the vaccine but rather to mechanical damage to the skin and subcutaneous tissue after injection with a jet injector. None of the side-effects necessitated medical treatment as the systemic reactions regressed within a few hours and the local reactions disappeared spontaneously within a few days.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Peukert, and J Pollter
[Antibody development in influenza vaccination with a polyvalent aluminum oxide adsorbed vaccine].
November 1975, Therapie der Gegenwart,
M Peukert, and J Pollter
Inactivated polyvalent influenza virus vaccine.
November 1967, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Peukert, and J Pollter
Asian influenza: the protective efficacy of polyvalent influenza vaccine.
October 1966, The Journal of the Oklahoma State Medical Association,
M Peukert, and J Pollter
POLYVALENT INFLUENZA VACCINE IN GENERAL PRACTICE.
October 1964, British medical journal,
M Peukert, and J Pollter
[On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
July 1975, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie,
M Peukert, and J Pollter
[Serological studies in preventive influenza vaccinations with aluminum oxide-adsorbed polyvalent vaccines].
December 1965, Zeitschrift fur Hygiene und Infektionskrankheiten; medizinische Mikrobiologie, Immunologie und Virologie,
M Peukert, and J Pollter
[Adsorbed influenza chemical vaccine in the immunization of schoolchildren].
April 1987, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M Peukert, and J Pollter
[INDUSTRIAL MEDICAL EXPERIENCES AFTER USE OF A POLYVALENT INFLUENZA VIRUS ADSORBATE VACCINE (INFLUENZA VACCINE ASTA)].
February 1964, Die Medizinische Welt,
M Peukert, and J Pollter
Effectiveness of polyvalent influenza A vaccine during an influenza A-prime epidemic.
May 1954, American journal of hygiene,
M Peukert, and J Pollter
The protective effect of polyvalent oil-adjuvant influenza vaccine in chdren.
August 1966, Pediatrics,
Copied contents to your clipboard!